Profound Medical Corp. (PROF) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 4.01
30Y Low2.9·High8.4
ROE
↓
N/A
—
5yr avg: -51.1%
30Y Low-206%·High-35%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PROF Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Profound Medical Corp. trades at 5.1x earnings, 8% below its 5-year average of 5.6x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 77%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $262M | $238M | $186M | $180M | $227M | $230M | $356M | $121M | — | — | — |
| Enterprise Value | $262M | $238M | $136M | $161M | $189M | $164M | $273M | $118M | — | — | — |
| P/E Ratio → | 5.12 | 5.58 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.28 | 14.78 | 18.29 | 24.98 | 33.95 | 33.44 | 48.68 | 29.11 | — | — | — |
| P/B Ratio | — | — | 3.08 | 5.76 | 4.36 | 2.85 | 3.65 | 8.44 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PROF EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.78 | 13.40 | 22.43 | 28.22 | 23.88 | 37.42 | 28.19 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
PROF Profitability
Margins and return-on-capital ratios measuring operating efficiency
Profound Medical Corp. earns an operating margin of -256.3%. Operating margins have expanded from -397.5% to -256.3% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.8% | 70.8% | 65.9% | 60.9% | 45.2% | 43.0% | 47.6% | 57.3% | 31.7% | 38.2% | — |
| Operating Margin | -256.3% | -256.3% | -309.6% | -397.5% | -480.9% | -440.7% | -258.3% | -357.1% | -776.0% | -451.9% | — |
| Net Profit Margin | 262.9% | 262.9% | -260.4% | -396.8% | -429.1% | -446.7% | -296.0% | -364.7% | -797.9% | -383.8% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -57.8% | -68.7% | -43.3% | -34.5% | -38.7% | -89.7% | -99.0% | -134.3% | -115.1% |
| ROA | 63.5% | 63.5% | -46.4% | -52.7% | -38.0% | -32.1% | -32.1% | -47.4% | -54.1% | -75.2% | -73.8% |
| ROIC | — | — | -200.8% | -161.4% | -168.8% | -151.8% | -110.2% | -136.7% | -180.8% | -378.6% | -327.2% |
| ROCE | -61.9% | -61.9% | -62.2% | -58.5% | -45.0% | -33.2% | -31.0% | -59.3% | -70.5% | -127.8% | -110.5% |
PROF Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.08 | 0.25 | 0.16 | 0.02 | 0.02 | 0.76 | 0.45 | 0.36 | 0.45 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.82 | -0.59 | -0.74 | -0.82 | -0.84 | -0.27 | -0.70 | -0.42 | -0.96 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -37.16 | -192.25 | -456.12 | -34.74 | -14.36 | -19.63 | -16.45 | -25.40 |
PROF Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio has improved from 6.58x to 10.52x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 10.52 | 6.58 | 14.82 | 18.56 | 20.32 | 2.77 | 4.81 | 1.64 | 4.54 |
| Quick Ratio | — | — | 9.64 | 5.48 | 12.92 | 16.78 | 19.22 | 2.33 | 4.35 | 1.51 | 4.46 |
| Cash Ratio | — | — | 8.36 | 4.12 | 11.12 | 16.16 | 17.45 | 1.80 | 3.89 | 1.04 | 4.21 |
| Asset Turnover | — | 0.26 | 0.14 | 0.16 | 0.10 | 0.08 | 0.07 | 0.14 | 0.06 | 0.18 | — |
| Inventory Turnover | — | — | 0.60 | 0.40 | 0.46 | 0.53 | 0.72 | 0.49 | 0.49 | 2.12 | 0.60 |
| Days Sales Outstanding | — | — | 252.91 | 369.51 | 346.59 | 74.88 | 371.35 | 289.84 | 289.58 | 334.27 | — |
PROF Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Profound Medical Corp. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 19.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 19.5% | 17.9% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $30M | $25M | $21M | $21M | $20M | $17M | $11M | $10M | $6M | $4M |
Peer Comparison
Compare PROF with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PROFYou | $262M | 5.1 | — | — | 70.8% | -256.3% | — | — | — |
 ISRG | $160B | 57.4 | 43.4 | 64.4 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 AEYE | $95M | -30.6 | — | — | 78.3% | -7.9% | -43.2% | -42.4% | — |
 EDAP | $134M | -6.0 | — | — | 41.4% | -32.0% | -38.9% | -65.7% | — |
 ARAY | $58M | -31.7 | 12.7 | — | 32.1% | 1.7% | -2.5% | 3.0% | 12.6 |
 GKOS | $8B | -41.2 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 NNOX | $117M | -2.0 | — | — | -94.0% | -502.9% | -27.8% | -27.9% | — |
 PHG | $26B | 24.9 | 10.7 | 24.7 | 45.2% | 8.0% | 7.8% | 6.4% | 3.2 |
 GE | $320B | 37.5 | 32.8 | 44.0 | 36.8% | 19.1% | 45.3% | 24.7% | 2.1 |
 GEHC | $28B | 13.6 | 10.1 | 18.6 | 40.0% | 13.4% | 21.6% | 13.3% | 3.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See PROF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PROF Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PROF vs ISRG
Side-by-side business, growth, and profitability comparison vs Intuitive Surgical, Inc..
Start ComparisonPROF — Frequently Asked Questions
Quick answers to the most common questions about buying PROF stock.
What is Profound Medical Corp.'s P/E ratio?
Profound Medical Corp.'s current P/E ratio is 5.1x. The historical average is 5.6x.
Is PROF stock overvalued?
Based on historical data, Profound Medical Corp. is trading at a P/E of 5.1x. Compare with industry peers and growth rates for a complete picture.
What are Profound Medical Corp.'s profit margins?
Profound Medical Corp. has 70.8% gross margin and -256.3% operating margin.